22111
document
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma : a prospectively planned combined survival analysis of two multicenter trials . BACKGROUND Fulvestrant is an estrogen receptor antagonist with no agonist effects . In the second-line treatment of advanced breast carcinoma , fulvestrant was shown previously to be as effective as the third-generation aromatase inhibitor , anastrozole , in terms of time to disease progression and objective response rates . The authors reported the overall survival results from these studies . METHODS A prospectively planned , combined , overall survival analysis was performed , including data from two Phase III trials that compared the efficacy and tolerability of fulvestrant ( 250 mg monthly ; n = 428 ) with anastrozole ( 1 mg daily ; n = 423 ) in the treatment of postmenopausal women with advanced breast carcinoma who had disease progression after receipt of previous endocrine treatment . RESULTS At an extended median follow-up of 27.0 months ( range , 0-66.9 months ) , 319 ( 74.5 % ) patients in the fulvestrant group and 322 ( 76.1 % ) patients in the anastrozole group had died . Prolonged survival was observed with both drugs , with 10-20 % of patients still alive > 5 years after randomization . The median overall survival was similar between treatments , being 27.4 months and 27.7 months in fulvestrant and anastrozole-treated patients , respectively ( hazards ratio , 0.98 ; 95 % confidence interval , 0.84-1.15 ; P = 0.809 ) . Fulvestrant continued to be well tolerated , and was associated with a significantly lower incidence of joint disorders compared with anastrozole ( P = 0.0234 ) . CONCLUSIONS The current analysis showed that fulvestrant was similar to anastrozole with respect to overall survival in the second-line treatment of postmenopausal women with advanced breast carcinoma .
22112
Intervention_Pharmacological
Fulvestrant
22113
Intervention_Pharmacological
anastrozole
22114
Intervention_Pharmacological
Fulvestrant
22115
Intervention_Pharmacological
fulvestrant
22116
Intervention_Pharmacological
anastrozole
22117
Intervention_Pharmacological
fulvestrant
22118
Intervention_Pharmacological
anastrozole-treated
22119
Intervention_Pharmacological
fulvestrant
22120
Outcome_Mortality
overall survival
22121
Outcome_Mortality
overall survival
22122
Outcome_Other
efficacy
22123
Outcome_Other
tolerability
22124
Outcome_Mortality
died
22125
Outcome_Mortality
Prolonged survival
22126
Outcome_Mortality
alive
22127
Outcome_Mortality
median overall survival
22128
Outcome_Physical
incidence of joint disorders
22129
Participant_Condition
postmenopausal
22130
Participant_Sex
women
22131
Participant_Condition
advanced breast carcinoma
22132
Participant_Sample-size
319
22133
Participant_Sample-size
322
22134
Participant_Condition
postmenopausal
22135
Participant_Sex
women
22136
Participant_Condition
advanced breast carcinoma